Lucy Therapeutics (LucyTx) has secured new funding from the International Rett Syndrome Foundation (IRSF) to invest in pioneering treatments for children and adults living with Rett syndrome, and to grow LucyTx’s groundbreaking treatment platform.
LucyTx develops therapies based on mitochondrial small-molecule treatments and biomarkers for neurological diseases. IRSF is a mission-driven advocacy foundation focused on funding research and supporting families impacted by Rett syndrome.
Lucy Therapeutics is a 2019 MassNextGen awardee. The MLSC’s Massachusetts Next Generation (MassNextGen) Initiative that aims to support a broad network of underrepresented entrepreneurs through funding, coaching, and network building.